Jonas Hallberg1, Viktor Kaldo2, Stefan Arver1, Cecilia Dhejne3, Jussi Jokinen4, Katarina Görts Öberg5. 1. Department of Medicine, Karolinska Institute, Stockholm, Sweden; ANOVA, Karolinska University Hospital, Stockholm, Sweden. 2. Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute and Stockholm Healthcare Services, Stockholm County Council, Stockholm, Sweden; Department of Psychology, Faculty of Health and Life Sciences, Linnaeus University, Växjö, Sweden. 3. Department of Medicine, Karolinska Institute, Stockholm, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute and Stockholm Healthcare Services, Stockholm County Council, Stockholm, Sweden. 4. Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institute and Stockholm Healthcare Services, Stockholm County Council, Stockholm, Sweden; Department of Clinical Sciences/Psychiatry, Umeå University, Umeå, Sweden. 5. Department of Medicine, Karolinska Institute, Stockholm, Sweden; ANOVA, Karolinska University Hospital, Stockholm, Sweden. Electronic address: katarina.gorts-oberg@sll.se.
Abstract
BACKGROUND:Hypersexual disorder (HD) is defined as a condition in which the individual loses control over engagement in sexual behaviors, leading to distress and negative effects on key life areas. Cognitive behavioral therapy (CBT) has been proven to reduce symptoms of hypersexual behavior; however, no randomized controlled study of CBT interventions for HD has been reported previously. AIM: To investigate the efficacy of group-administered CBT for HD. METHODS:Male participants (n = 137) diagnosed with HD, were randomized between 7 weeks of group-administered CBT (n = 70) and a waitlist control receiving the intervention after 8 weeks (n = 67). Measurements were administered at pre-, mid-, and posttreatment, with follow-up after 3 and 6 months. OUTCOMES: The primary outcome was the Hypersexual Disorder: Current Assessment Scale (HD:CAS), and secondary outcomes were the Sexual Compulsivity Scale (SCS) and measures of depression (Montgomery-Åsberg Depression Rating Scale (MADRS-S), psychological distress (Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM), and treatment satisfaction (CSQ-8). RESULTS: A significantly greater decrease in HD symptoms and sexual compulsivity, as well as significantly greater improvements in psychiatric well-being, were found for the treatment condition compared with the waitlist. These effects remained stable at 3 and 6 months after treatment. CLINICAL IMPLICATIONS: CBT can ameliorate HD symptoms and psychiatric distress, suggesting that the CBT program may serve as a first-line treatment in clinical settings. STRENGTHS & LIMITATIONS: This is the first randomized controlled study evaluating the efficacy of a CBT program in a rather large sample of HD-specific diagnosed men. The long-term treatment effects are vague due to the low response rate on follow-up measurements, and the efficacy of this program for hypersexual women remains unknown. CONCLUSION: This study supports the efficacy of a group-administered CBT program as a treatment option for HD; however, future studies should include women, comprise dismantling analysis of the constituting interventions, and evaluate other treatment formats, for example, administration via the Internet. Hallberg J, Kaldo V, Arver S, et al. A Randomized Controlled Study of Group-Administered Cognitive Behavioral Therapy for Hypersexual Disorder in Men. J Sex Med 2019;16:733-745.
RCT Entities:
BACKGROUND:Hypersexual disorder (HD) is defined as a condition in which the individual loses control over engagement in sexual behaviors, leading to distress and negative effects on key life areas. Cognitive behavioral therapy (CBT) has been proven to reduce symptoms of hypersexual behavior; however, no randomized controlled study of CBT interventions for HD has been reported previously. AIM: To investigate the efficacy of group-administered CBT for HD. METHODS: Male participants (n = 137) diagnosed with HD, were randomized between 7 weeks of group-administered CBT (n = 70) and a waitlist control receiving the intervention after 8 weeks (n = 67). Measurements were administered at pre-, mid-, and posttreatment, with follow-up after 3 and 6 months. OUTCOMES: The primary outcome was the Hypersexual Disorder: Current Assessment Scale (HD:CAS), and secondary outcomes were the Sexual Compulsivity Scale (SCS) and measures of depression (Montgomery-Åsberg Depression Rating Scale (MADRS-S), psychological distress (Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM), and treatment satisfaction (CSQ-8). RESULTS: A significantly greater decrease in HD symptoms and sexual compulsivity, as well as significantly greater improvements in psychiatric well-being, were found for the treatment condition compared with the waitlist. These effects remained stable at 3 and 6 months after treatment. CLINICAL IMPLICATIONS: CBT can ameliorate HD symptoms and psychiatric distress, suggesting that the CBT program may serve as a first-line treatment in clinical settings. STRENGTHS & LIMITATIONS: This is the first randomized controlled study evaluating the efficacy of a CBT program in a rather large sample of HD-specific diagnosed men. The long-term treatment effects are vague due to the low response rate on follow-up measurements, and the efficacy of this program for hypersexual women remains unknown. CONCLUSION: This study supports the efficacy of a group-administered CBT program as a treatment option for HD; however, future studies should include women, comprise dismantling analysis of the constituting interventions, and evaluate other treatment formats, for example, administration via the Internet. Hallberg J, Kaldo V, Arver S, et al. A Randomized Controlled Study of Group-Administered Cognitive Behavioral Therapy for Hypersexual Disorder in Men. J Sex Med 2019;16:733-745.
Authors: Benny Liberg; Katarina Görts-Öberg; Jussi Jokinen; Josephine Savard; Cecilia Dhejne; Stefan Arver; Johannes Fuss; Martin Ingvar; Christoph Abé Journal: J Behav Addict Date: 2022-05-30 Impact factor: 7.772
Authors: Dan J Stein; Peter Szatmari; Wolfgang Gaebel; Michael Berk; Eduard Vieta; Mario Maj; Ymkje Anna de Vries; Annelieke M Roest; Peter de Jonge; Andreas Maercker; Chris R Brewin; Kathleen M Pike; Carlos M Grilo; Naomi A Fineberg; Peer Briken; Peggy T Cohen-Kettenis; Geoffrey M Reed Journal: BMC Med Date: 2020-01-27 Impact factor: 8.775
Authors: Piet van Tuijl; Aerjen Tamminga; Gert-Jan Meerkerk; Peter Verboon; Ruslan Leontjevas; Jacques van Lankveld Journal: Int J Environ Res Public Health Date: 2020-09-21 Impact factor: 3.390
Authors: John Flanagan; Andreas Chatzittofis; Adrian Desai E Boström; Jonas Hallberg; Katarina Görts Öberg; Stefan Arver; Jussi Jokinen Journal: J Clin Endocrinol Metab Date: 2022-04-19 Impact factor: 6.134
Authors: Martina Goslar; Max Leibetseder; Hannah M Muench; Stefan G Hofmann; Anton-Rupert Laireiter Journal: J Behav Addict Date: 2020-04-01 Impact factor: 6.756